vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and Q32 Bio Inc. (QTTB). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.9M, roughly 1.3× Q32 Bio Inc.). Q32 Bio Inc. runs the higher net margin — 2991.2% vs -265.2%, a 3256.4% gap on every dollar of revenue.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing targeted antibody-based immunotherapies for autoimmune disorders, inflammatory conditions and rare immunological diseases with unmet medical needs, operating primarily across North America and European markets.
BOLT vs QTTB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $1.9M |
| Net Profit | $-6.6M | $57.7M |
| Gross Margin | — | — |
| Operating Margin | -283.4% | — |
| Net Margin | -265.2% | 2991.2% |
| Revenue YoY | — | — |
| Net Profit YoY | 58.4% | 506.9% |
| EPS (diluted) | $-9.38 | $4.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $1.9M | ||
| Q3 25 | $2.2M | $-220.0K | ||
| Q2 25 | $1.8M | $-284.0K | ||
| Q1 25 | $1.2M | $-371.0K | ||
| Q4 24 | $0 | $0 | ||
| Q3 24 | $1.1M | $0 | ||
| Q2 24 | $1.3M | $0 | ||
| Q1 24 | $5.3M | $0 |
| Q4 25 | $-6.6M | $57.7M | ||
| Q3 25 | $-7.1M | $-7.4M | ||
| Q2 25 | $-8.6M | $-9.5M | ||
| Q1 25 | $-11.0M | $-11.0M | ||
| Q4 24 | $-15.9M | $-14.2M | ||
| Q3 24 | $-15.2M | $-17.6M | ||
| Q2 24 | $-21.2M | $-17.0M | ||
| Q1 24 | $-10.8M | $1.0M |
| Q4 25 | -283.4% | — | ||
| Q3 25 | -355.1% | 3444.1% | ||
| Q2 25 | -510.5% | 3229.2% | ||
| Q1 25 | -991.4% | 3296.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1441.1% | — | ||
| Q2 24 | -1772.3% | — | ||
| Q1 24 | -324.1% | — |
| Q4 25 | -265.2% | 2991.2% | ||
| Q3 25 | -329.4% | 3358.6% | ||
| Q2 25 | -474.6% | 3341.2% | ||
| Q1 25 | -903.4% | 2973.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1330.1% | — | ||
| Q2 24 | -1662.4% | — | ||
| Q1 24 | -205.0% | — |
| Q4 25 | $-9.38 | $4.70 | ||
| Q3 25 | $-3.72 | $-0.60 | ||
| Q2 25 | $-4.46 | $-0.78 | ||
| Q1 25 | $-0.29 | $-0.90 | ||
| Q4 24 | $-13.73 | $2.63 | ||
| Q3 24 | $-7.93 | $-1.46 | ||
| Q2 24 | $-11.12 | $-1.42 | ||
| Q1 24 | $-0.28 | $-6.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $48.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $42.0M |
| Total Assets | $56.7M | $61.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $48.3M | ||
| Q3 25 | $31.9M | $49.0M | ||
| Q2 25 | $34.8M | $54.8M | ||
| Q1 25 | $38.8M | $65.5M | ||
| Q4 24 | $47.3M | $78.0M | ||
| Q3 24 | $53.8M | $89.1M | ||
| Q2 24 | $73.7M | $97.7M | ||
| Q1 24 | $91.3M | $115.5M |
| Q4 25 | $26.5M | $42.0M | ||
| Q3 25 | $32.1M | $-18.4M | ||
| Q2 25 | $38.8M | $-12.2M | ||
| Q1 25 | $46.8M | $-4.0M | ||
| Q4 24 | $57.2M | $5.7M | ||
| Q3 24 | $72.0M | $18.3M | ||
| Q2 24 | $85.9M | $33.5M | ||
| Q1 24 | $104.2M | $48.8M |
| Q4 25 | $56.7M | $61.8M | ||
| Q3 25 | $65.1M | $57.8M | ||
| Q2 25 | $75.5M | $66.1M | ||
| Q1 25 | $85.9M | $79.1M | ||
| Q4 24 | $99.6M | $92.3M | ||
| Q3 24 | $109.3M | $104.5M | ||
| Q2 24 | $124.2M | $124.2M | ||
| Q1 24 | $142.9M | $152.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-6.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.11× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-6.2M | ||
| Q3 25 | $-9.7M | $-4.2M | ||
| Q2 25 | $-9.6M | $-10.7M | ||
| Q1 25 | $-13.4M | $-12.5M | ||
| Q4 24 | $-14.4M | $-11.4M | ||
| Q3 24 | $-14.0M | $-19.5M | ||
| Q2 24 | $-16.1M | $-22.2M | ||
| Q1 24 | $-16.8M | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | $-14.0M | $-19.6M | ||
| Q2 24 | — | $-22.2M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | -0.11× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -14.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
